US1663201A - Process for making bismuth tartrates and product produced thereby - Google Patents
Process for making bismuth tartrates and product produced thereby Download PDFInfo
- Publication number
- US1663201A US1663201A US112398A US11239826A US1663201A US 1663201 A US1663201 A US 1663201A US 112398 A US112398 A US 112398A US 11239826 A US11239826 A US 11239826A US 1663201 A US1663201 A US 1663201A
- Authority
- US
- United States
- Prior art keywords
- bismuth
- tartrates
- tartrate
- sodium
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title description 19
- 230000008569 process Effects 0.000 title description 15
- SULICOHAQXOMED-UHFFFAOYSA-H bis(5,6-dihydroxy-4,7-dioxo-1,3,2-dioxabismepan-2-yl) 2,3-dihydroxybutanedioate Chemical class [Bi+3].[Bi+3].[O-]C(=O)C(O)C(O)C([O-])=O.[O-]C(=O)C(O)C(O)C([O-])=O.[O-]C(=O)C(O)C(O)C([O-])=O SULICOHAQXOMED-UHFFFAOYSA-H 0.000 title description 5
- 229910052797 bismuth Inorganic materials 0.000 description 43
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 27
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 21
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 18
- 239000011975 tartaric acid Substances 0.000 description 18
- 235000002906 tartaric acid Nutrition 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 16
- 229910052783 alkali metal Inorganic materials 0.000 description 13
- 239000003513 alkali Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 150000001340 alkali metals Chemical class 0.000 description 9
- 150000001622 bismuth compounds Chemical class 0.000 description 8
- -1 bismuth tartra-tes Chemical class 0.000 description 8
- 150000003388 sodium compounds Chemical class 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- TZSXPYWRDWEXHG-UHFFFAOYSA-K bismuth;trihydroxide Chemical compound [OH-].[OH-].[OH-].[Bi+3] TZSXPYWRDWEXHG-UHFFFAOYSA-K 0.000 description 7
- 229940049676 bismuth hydroxide Drugs 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- SULICOHAQXOMED-YDXPQRMKSA-H dibismuth;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Bi+3].[Bi+3].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O SULICOHAQXOMED-YDXPQRMKSA-H 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 150000001621 bismuth Chemical class 0.000 description 4
- YLQCOSAFPRCDKP-UHFFFAOYSA-J bismuth;sodium;2,3-dihydroxybutanedioate Chemical compound [Na+].[Bi+3].[O-]C(=O)C(O)C(O)C([O-])=O.[O-]C(=O)C(O)C(O)C([O-])=O YLQCOSAFPRCDKP-UHFFFAOYSA-J 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 150000003112 potassium compounds Chemical class 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000006379 syphilis Diseases 0.000 description 4
- WHXKANKVTGLLNK-UHFFFAOYSA-L tribismuth 2,3-dihydroxybutanedioate Chemical compound C(=O)([O-])C(O)C(O)C(=O)[O-].[Bi+3].[Bi+3].[Bi+3] WHXKANKVTGLLNK-UHFFFAOYSA-L 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical group [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940095064 tartrate Drugs 0.000 description 3
- 150000003892 tartrate salts Chemical class 0.000 description 3
- 241000700159 Rattus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- KRORHUBQMQNGLH-UHFFFAOYSA-L tetrabismuth sodium 2,3-dihydroxybutanedioate Chemical compound C(=O)([O-])C(O)C(O)C(=O)[O-].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[Na+] KRORHUBQMQNGLH-UHFFFAOYSA-L 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VAWXBFJGJCXGML-UHFFFAOYSA-D tribismuth potassium 2,3-dihydroxybutanedioate Chemical group C(=O)([O-])C(O)C(O)C(=O)[O-].[Bi+3].[Bi+3].[Bi+3].[K+].C(=O)([O-])C(O)C(O)C(=O)[O-].C(=O)([O-])C(O)C(O)C(=O)[O-].C(=O)([O-])C(O)C(O)C(=O)[O-].C(=O)([O-])C(O)C(O)C(=O)[O-] VAWXBFJGJCXGML-UHFFFAOYSA-D 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- SUYPPESIALRPMQ-UHFFFAOYSA-D C(=O)([O-])C(O)C(O)C(=O)[O-].[Bi+3].[Bi+3].[Bi+3].[Na+].C(=O)([O-])C(O)C(O)C(=O)[O-].C(=O)([O-])C(O)C(O)C(=O)[O-].C(=O)([O-])C(O)C(O)C(=O)[O-].C(=O)([O-])C(O)C(O)C(=O)[O-] Chemical compound C(=O)([O-])C(O)C(O)C(=O)[O-].[Bi+3].[Bi+3].[Bi+3].[Na+].C(=O)([O-])C(O)C(O)C(=O)[O-].C(=O)([O-])C(O)C(O)C(=O)[O-].C(=O)([O-])C(O)C(O)C(=O)[O-].C(=O)([O-])C(O)C(O)C(=O)[O-] SUYPPESIALRPMQ-UHFFFAOYSA-D 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910000416 bismuth oxide Inorganic materials 0.000 description 1
- DSQJVSSALQTTFS-UHFFFAOYSA-J bismuth;potassium;2,3-dihydroxybutanedioate Chemical compound [K+].[Bi+3].[O-]C(=O)C(O)C(O)C([O-])=O.[O-]C(=O)C(O)C(O)C([O-])=O DSQJVSSALQTTFS-UHFFFAOYSA-J 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- TYIXMATWDRGMPF-UHFFFAOYSA-N dibismuth;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Bi+3].[Bi+3] TYIXMATWDRGMPF-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 229940079905 intestinal adsorbents bismuth preparations Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-N iodic acid Chemical class OI(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-N 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate group Chemical group [N+](=O)([O-])[O-] NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000004552 water soluble powder Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/94—Bismuth compounds
Definitions
- This invention relates to improvements in the manufacture and composition of bismuth tartrates, especially intended for the treatment of syphilis.
- Dispensatory states on page 912 that while thepresence of a certain amount of potassium in the bloodis essential for vital activity, a' very slight in crease in its percentage has a deleterious influence on many organs.
- the injection of a potassium salt into the circulation weakens the contractile power of all muscle fibers but afi'ects' especially the heart and blood vessels. It also exercises a marked depressant action upon the central nervous system, including the spinal cord, brain and medulla. Although the depressant action of potassium is strong when injected directly into, the blood stream, when-taken by the mouth it exercisesvery little influence upon the circulation. This is due to the fact that it is excreted by the kidneys so rapidly that it cantartrat'e" seemed desirable and of value. No
- the alkalinity can be also decreased by absorption of iodine, with the formation of colorless solutions of iodides and iodates of theitetra-bismuth tartrates, which also seem stable at room temperatures.
- the mixture atthe end of six days was filtered through a porous glass Buchner suction filter or through a hard filter paper.
- the base containing four atoms of bismuthto every molecule of tartaric acid can be isolated, by simple neutralization and otherwise, and will dissolve in a gram equivalent of alkali, alsolubility greatly in excess of that shown by the bismuth coinpoundsheretofore considered suitable for such purpose, it is particularly well adapted for use in medicine generally as well as for the particingly, the invention is to be given a broad interpretation and the composition and process are not to be limited in proportions or procedure other than as indicated in the appended claims.
- a process for making bismuth tartratesv which consists in treating a basic bismuth compound with analkali and tartaric acld at not exceeding normal room temperature. '2; A process of making bismuth tartrates which-consists in treating a basic bismuth compound with an alkali metal hydroxlde trate, but suificiently low to prevent the for- ;mation of substantial amounts of tri-bis v muth tartrates.
- a process for making bismuth tartrates which-consists in treating a basicbismuth compound with an alkali and tartaric acid temperature.
- a process for making a sodium bismuth tartrate comprising treatlng a basic bismuth 'taric acid at not exceed1ng normal room compound with sodium hydroxide and tartemperature, separating ofi the excess bisbismuth tartrate with alcohol, substantially as described.
- a process for making an alkali metal muth salts, and precipitating the sodium bismuth tartrate comprising treating a basic bismuth compound with an alkali metal hy droxide and tartaric acid at not exceeding normal room temperature.
- a process of makmg an alkali metal bismuth tartrate comprising treating bismuth hydroxide with? an alkali metal hydroxide and tartaric acid -while maintaining the temperature at not exceeding normal room temperature.
- a process for making an alkali metal bismuth tartrate comprising treating a basic bismuth compound with an alkali metal hydroxide and tartaric acid at not exceeding normalroom temperature, separating o'flf the excess bismuth salt, and precipitating the alkali metal'bismuth tartrate with alcohol,-
- a process for making alkali metal tetra-bismuth tartrates comprising treating a basic bismuth compound with an alkali metal hydroxide and tartaric acid at n0t exceeding normal room temperature.
- a process of making alkali metal tetra-bismuth tartrates which comprises treating bismuth hydroxides Witha solution of an alkali metal hydroxide and tartaric acid at approximately 1415 C.
- a process tor making an alkali metal tetra-bismuth tartrate comprising treating a basic bismuth compound with an alkali and tartaric acid at not exceeding normal room temperature, separating ofi-the excess bismuth salts, and precipitating the alkali metal tetra-bismuth tartrate with alcohol, substantially as described.
- a bismuth tartrate havlng four atoms of bismuth for every molecule of tartaric acid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
I ration.
Patented PHILIP ADOLPH KOBER, or EVANSTON, ILLrnoIs, Assrenoaro a. D. sEARLE & 00., or cnrcaeo, rumors, A ooaronarron or rumors- PROCESS FOR MAKING IBISMUTH TARTRATES AND PRODUCT PRODUCED THEREBY.
No Drawing.
This invention relates to improvements in the manufacture and composition of bismuth tartrates, especially intended for the treatment of syphilis.
The use of bismuth therapy in syphilis since its introduction in France a few years ago has gradually grown so that it has become a valuable addition to our regular'antisyphilitic chemotherapeutic agents, the arsenicals.
L. E. Warren of the Chemical Laboratories ofthe American Medical Association, (Journ. Amer. Med. Ass. 84, 1067, 1925) writing under the title What is the composition of bismuth tartra-tes used in the treatment of syphilis, stated as part of his summary that the fact that the bismuth content inthe various bismuth preparations-' the satisfactory as well as the unsatisfac toryis within such a wide range (31-73%) emphasizes the necessity for clinicians to inquire carefully concerning the. composition of the bismutli products they use, particularlyin reference to the bismuth content,-
before making reports concerning the alleged efi'ectiv'eness of this, that or the other prepa- This statement was based upon analyses of practically all, seven in number, of the bismuth preparations on the market.
Theoretically and actually found, there are many difierent compounds of bismuth and tartaric acid. Of the water soluble preparations which are probably more efiec tive on account of speedier absorption and greater enetration, all of them also containin a dition to bismuth and tartaric acid, alkali metals, either sodium or potassium or both. Ordinary bismuth salts of tartaric acid have too great a tendency to hydrolyze into insoluble bismuth oxide or basic salts to be desirable for syphilitic treatment.
.Theretore the more firmly the bismuth is bound tothe tartaric acid, in the form of a complex salt, the greater efiicacy can be expected as the-bismuth must remain in the form of a. soluble organic complex long enough to allow absorption from the site of injection and to be distributed throughout the body by means of the blood stream.
Application filed May 28,
1926. Serial No. 112,398;
Chemical tests. show that the most firmly bound. bismuth compounds of those heretofore isolated, are the tri-bismuth alkali tartrates, of which the only known example is potassium tri-bismuth tartrate. The following formula has been assigned to this com pound:
'O0-Bi=i0 H- OBi=0 H- O-Bi=0 4-H=o O Anhydrous With water of 72. 8% hydration Bismuth a Bismuth This compound and its preparation was first described by Rosenhei'm and Vogelsang (Zeitschrift fiir Anorg. Chem. 48, 205, (1906)) and has been 011' the market and used clinically both here and abroad.
So far as I am aware no similar sodium product has been prepared, although theoretically it might have some advantages over the potassium compound. To manyworkers in pharmacology and medicine, potassium compounds of therapeutic agents are not so desirable as the corresponding sodium compounds. On this subject the'U.S.-
Dispensatory (twentieth edition) states on page 912 that while thepresence of a certain amount of potassium in the bloodis essential for vital activity, a' very slight in crease in its percentage has a deleterious influence on many organs. The injection of a potassium salt into the circulation weakens the contractile power of all muscle fibers but afi'ects' especially the heart and blood vessels. It also exercises a marked depressant action upon the central nervous system, including the spinal cord, brain and medulla. Although the depressant action of potassium is strong when injected directly into, the blood stream, when-taken by the mouth it exercisesvery little influence upon the circulation. This is due to the fact that it is excreted by the kidneys so rapidly that it cantartrat'e" seemed desirable and of value. No
method was'favailable in the literaturev which described the'isolationof such a sodium compound; Bosenheim and Vogelsang attempted to isolate the sodium compound but they stated-it would not crystallize out similarly to the potassium compound. Klau'der makes the statement that the sodium salt is unstable which indicates in the light of the work report'e'd'here that the sodium compound had not been successfully isolated, or at least a sodium compound similar to the one de- Tcribed in' this disclosure had not been isoated.
I 'On'considering the method of Rosenheim J and Yogelsang, which consists in digesting bismuth subuitrate with tartaric acid and an excess of alkali whileheating, I came to the conclusion, that from thermo-dynamicreasoning, the reaction ought to be conducted in the cold or at least without heating.
Furthermore since the nitrate group does not enter i'nto' the composition of the compound desired, its presence. may interfere with the reaction. For these reasons I tried the reaction with a slight excess of sodium hydroxide in the cold, using bismuth. hy-
droxide as a source-of bismuth and shaking with a ,mechanical shaker. The bismuth hydroxide at first dissolved fairly rapidly,
- but.soon .i t dissolved more and more slowly.
Howeyefianumber of experiments showed that the longenI shook the mixture, the more'bismuth hydroxide dissolved. At the end ofiabout 144 hours (6 days about) the mixtu're' seemed to come to an equilibrium and no more bismuth hydroxide seemed to dissolve. On filtering'I had in solution, of cours'e, a sodium bismuth tartrate. A few experiments with small portions of the filtrate soon showed that a half volume of 95%alcohol gave me a copious yield of P116- cipitate. The precipitate after .washing w1th'1 5 0% alcohol several times to remove the mother liquor and finally-with 95% al-.
cohol'and drying in the air at room temperature gave a water soluble powder containing 72.9% of bismuth'and 4.6% of water of hydration, or for an anhydrous substance 76.4% of bismuth, Since the anhydrous sodium tri-bismuth tartrate could not contain more than 74.2% of bismuth, it was evi dent that this'preparation contained more than three molecules of bismuth. The the'o retical per cent for bismuth and water for sodium tetra-bismuth tartrate and sodium I i tri-bisniuth tartrate is as follows:
' From this data I was forced to the conclusion that this sodium tartrate compound was sodium tetra-bismuth tartrate and I have tentatively assigned the following formula to it.
Sodium tetra-bismuth tai'trate 77.1% Bi Potassium tetra-bismuth tartrate 75.8% K
- If these findings and c'onclusions with the sodium compound were correct, then it ought to be possible to get a potassium compound of similar composition with even more bismuth content than any found on the-market, since most of them approximate inbismuth content that of a tri-bismuth tartrate.
On substituting potassium hydroxide for sodium hydroxide in the method developed for the sodium compound, I had no difli cultyin getting a fair yield on the first trial using otherwise the exact technic as I did for the sodium process. It is probable that by using more suitable proportions of alcohol, since the solubilities of the. two substances undoubtedlydiifer, a greater yield would have been obtained. However, the analytical data; agree with the theory for a tetra-bismuth tartrate even more. closely than did the sodium compound:
. lHzO 21320 Anhy- Potassium compound drous 31% 11.0% 121% H:O% Bi% Theory for tri-bismuth tartrate. 72.9 2.05 71.4 4.02 70.0 Actually found 75.8 2.76 73.8 Theory for tetra-bismuth tartra e 8 3.16 73 3 then dissolve. Accurate solubility determi- Inc nations have not yet been made, indications are that the solubility at room temperatures Solutions of these tetra-bismuth tartrates are alkaline in harmony with the formula, and so far as we know are perfectly stable. The alkalinity. can be decreased by titrating with N/lO sulphuric acid, using phenolphthalein as an indicator, to a hydrogen ion concentration of 'a P 8. l8.6, at which point the solutions up to seem stable indefinitely. Heating such solutions to 70 C. for 45 minutes seems to cause no change whatever, while heating5 minutes at100 (I. produced only a very slight cloud and a slight increase in alkalinity, butwhich'on cooling slowly returned to its original state.
The alkalinity can be also decreased by absorption of iodine, with the formation of colorless solutions of iodides and iodates of theitetra-bismuth tartrates, which also seem stable at room temperatures.
On adding a gram equivalent of acid to 1 solutions of tetra-bismuth tart-rates a precipitate is produced, which redissolves in an equivalent amount of alkali, indicating that the precipitate is a tetra-bismuth tartrate base. Large excess of acids decompose the base so that it does not .redissolve in an equivalent amount of alkali. This base is very gelatinous and seems to -be close to a permanent suspensoid. Ralziss, Severac and W1n1cov (Amer.
' Journ. of Olin. Med. August 1923) quote Sazerac and Levaditi, who werevthe first to study bismuth tartrates as curative agents for syphilis, as stating that their sodium and potassium bismuth tartrate killed'white rats when 5 milligrams per kilogram of animal was injected intravenously. Raiziss and associates found their potassium tribismuth tartrate was tolerated up to 10 milligrams per kilogram, but killing at 15 milligrams per kilogram. Our prehminarymesults with white rats indicate that these tetra-bismuth tartrates are considerably less toxic being tolerated when injected intravenously up to about-'25 milligrams per kilogram of body weight.
The r sults of my investigation as above described confirm my belief that the temperature at which the reaction between the alkali and the bismuth compound is carried out is important in determining whether the tri-bismuth tartrates or the tetra-bismuth tartrates will be formed. One of the essential features or my process of producing the new is carried on that it shall be maintained be- I low a point where substantial amounts of tribismuth tartrates are formed.
to about 1500 cc. Then with rapid stirring 300 cc. of saturated sodium hydroxide (50%) were added to precipitate the bismuth as hydroxide in a finely divided condition.
upon a suction filter, washed and resuspended in water, filtered, "washed with distilled water three ormore times until all of the mother liquor had been removed.
The preclpitate was then filtered"- Into a liter bottle or flask were'weighed. I l
25.0 grams of tartaric acid and 7 5 cc. of distilled water added. Then 28 cc. of saturated'sodium hydroxide (50%) were added withstirring and cooling. .When the liquid had cooled to 1415 C. the bismuth hydroxide, prepared as described above was added and after stoppering the bottle or flask securely, the mixture was shaken on a 7 mechanical shaker for from one hour to two hours, at three hour intervals during the first day. This shaking was repeated two or more times a day for 6 to 7.days. Longer standing or shaking caused no harm, but the amount of bismuth hydroxide ,dissolved by the alkaline tartrate solution was but slightly increased over the amount dissolved during the first six days. Attempts to shorten the period by heating decreas'edthe amount and purity of the yield.
The mixture atthe end of six days was filtered through a porous glass Buchner suction filter or through a hard filter paper.
'After'washing the undissolved bismuth 'hydroxide with 50 cc. 'of distilled water, the total filtrate equalled 350 cc.
not
On adding 175 cc. of 95% alcohol to the I filtrate withstirring, a copious precipitate was obtained, which was filtered on a Buchn'er funnel with suction, washed and sus pended in 100 'cc. of 50% alcohol, filtered and washed, ,resuspended, filtered and washed with 95% alcohol three or four times or until the filtrate was neutral to litmus paper. After drying 'at room temperature for several days, the yield was in the neigh borhood of grams or 89%. On substi -tuting the sameproportion of potassium hy= droxide for sodium hydroxide, the yieldwas about 30%.
That these tetra-bismuth tartrates have never before been isolated is indicated by the high content ofbismuth, by the stability of the aqueous solutions, and by the rela tively low toxicity, to ofthat of the products made by Raiziss and A; of that.
made by Sazerac' and Levaditi, the French originators of-bismuth therapy; I
Since in'this disclosurevl have shown how to form thesenew salts or compounds easily, and therefore have demonstrated the fundamental conditions under which such comular application above mentioned. Accord-' and tartaric acid at a temperature promoting the formation of a tetra-bismuth tar-' pounds are made, it will be understood that other alkalies, such .as ammonium and lithium, etc., can be used 'to produce the correspending-compounds, or that any combination o'gt'alkalies may be used to replace a single alkali, producing a bismuth tartrate containing in its composition two or more diiferent alkalies. Furthermore since the base containing four atoms of bismuthto every molecule of tartaric acid can be isolated, by simple neutralization and otherwise, and will dissolve in a gram equivalent of alkali, alsolubility greatly in excess of that shown by the bismuth coinpoundsheretofore considered suitable for such purpose, it is particularly well adapted for use in medicine generally as well as for the particingly, the invention is to be given a broad interpretation and the composition and process are not to be limited in proportions or procedure other than as indicated in the appended claims.
What isclaimed is:
1. A process for making bismuth tartratesv which consists in treating a basic bismuth compound with analkali and tartaric acld at not exceeding normal room temperature. '2; A process of making bismuth tartrates which-consists in treating a basic bismuth compound with an alkali metal hydroxlde trate, but suificiently low to prevent the for- ;mation of substantial amounts of tri-bis v muth tartrates.
3. A process for making bismuth tartrates which-consists in treating a basicbismuth compound with an alkali and tartaric acid temperature.
at not exceeding normal room temperature, separating off the'excess of bismuth salts,
and precipitating the bismuth tartrate'with- 6. A process for making a sodium bismuth tartrate comprising treatlng a basic bismuth 'taric acid at not exceed1ng normal room compound with sodium hydroxide and tartemperature, separating ofi the excess bisbismuth tartrate with alcohol, substantially as described. Y
7. A process for making an alkali metal muth salts, and precipitating the sodium bismuth tartrate comprising treating a basic bismuth compound with an alkali metal hy droxide and tartaric acid at not exceeding normal room temperature. v
8. A process of makmg an alkali metal bismuth tartrate comprising treating bismuth hydroxide with? an alkali metal hydroxide and tartaric acid -while maintaining the temperature at not exceeding normal room temperature.
9. A process for making an alkali metal bismuth tartrate comprising treating a basic bismuth compound with an alkali metal hydroxide and tartaric acid at not exceeding normalroom temperature, separating o'flf the excess bismuth salt, and precipitating the alkali metal'bismuth tartrate with alcohol,-
substantially. as described.
10. A process for making alkali metal tetra-bismuth tartrates comprising treating a basic bismuth compound with an alkali metal hydroxide and tartaric acid at n0t exceeding normal room temperature. 11..A process of making alkali metal tetra-bismuth tartrates .which comprises treating bismuth hydroxides Witha solution of an alkali metal hydroxide and tartaric acid at approximately 1415 C.
12. A process tor making an alkali metal tetra-bismuth tartrate comprising treating a basic bismuth compound with an alkali and tartaric acid at not exceeding normal room temperature, separating ofi-the excess bismuth salts, and precipitating the alkali metal tetra-bismuth tartrate with alcohol, substantially as described.
13.-.A soluble bismuth tartrate; having over 72.9% ofbismuth.
'14. A soluble alkali metal bismuth tartrate. having over 7 2.9% of bismuth.
15. An alkali metal bismuth tartrate hav- 1 ing four atoms of bismuth for. every molecule of tartaric acid. i
16. A bismuth tartrate havlng four atoms of bismuth for every molecule of tartaric acid.
17. A sodium bismuth tartrate four atoms of bismuth to every molecule of tartaric acid? In testimony whereof, I have signed my name to this specification this twenty-second day of May, 1926. 4
PHILIP ADOLPH KOBER.
having
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US112398A US1663201A (en) | 1926-05-28 | 1926-05-28 | Process for making bismuth tartrates and product produced thereby |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US112398A US1663201A (en) | 1926-05-28 | 1926-05-28 | Process for making bismuth tartrates and product produced thereby |
Publications (1)
Publication Number | Publication Date |
---|---|
US1663201A true US1663201A (en) | 1928-03-20 |
Family
ID=22343678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US112398A Expired - Lifetime US1663201A (en) | 1926-05-28 | 1926-05-28 | Process for making bismuth tartrates and product produced thereby |
Country Status (1)
Country | Link |
---|---|
US (1) | US1663201A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965382A (en) * | 1989-01-25 | 1990-10-23 | Eurosearch S.R.L. | Bismuth-containing compositions suitable for therapeutic use |
US6482865B1 (en) * | 2000-04-12 | 2002-11-19 | Gastropal Partners | Method for preparing colloidal solution of bismuth sodium tartrate |
US20030096861A1 (en) * | 2000-04-12 | 2003-05-22 | Gastropal Partners | Method for preparing colloidal solution of bismuth sodium tartrate |
-
1926
- 1926-05-28 US US112398A patent/US1663201A/en not_active Expired - Lifetime
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965382A (en) * | 1989-01-25 | 1990-10-23 | Eurosearch S.R.L. | Bismuth-containing compositions suitable for therapeutic use |
US6482865B1 (en) * | 2000-04-12 | 2002-11-19 | Gastropal Partners | Method for preparing colloidal solution of bismuth sodium tartrate |
US20030096861A1 (en) * | 2000-04-12 | 2003-05-22 | Gastropal Partners | Method for preparing colloidal solution of bismuth sodium tartrate |
US6699912B2 (en) | 2000-04-12 | 2004-03-02 | Gastropal Partners | Method for preparing colloidal solution of bismuth sodium tartrate |
US6743827B1 (en) | 2000-04-12 | 2004-06-01 | Fernando Palafox, Sr. | Method for preparing colloidal solution of bismuth sodium tartrate |
US20050035177A1 (en) * | 2000-04-12 | 2005-02-17 | Gastropal Partners | Method for preparing colloidal solution of bismuth sodium tartrate |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US1663201A (en) | Process for making bismuth tartrates and product produced thereby | |
Smith et al. | B12 vitamins (cobalamins). 2. Neutral, basic and acidic cobalamins | |
CH620362A5 (en) | ||
DE2139516C3 (en) | 3,4-Dihydroxybenzyl alcohol derivatives, their acid addition salts, processes for their preparation and pharmaceuticals | |
US2498174A (en) | Aluminum hexacarbamide periodide as water disinfectant | |
Kucera et al. | The Catalytic Chlorination of Dioxane1 | |
Vuletić et al. | Co-ordination complexes of niobium and tantalum XVII. diperoxotetrafluoro-niobates (V) and tantalates (V) | |
Matoush et al. | Synthesis and Properties of Some Fluoro-bis-(ethylenediamine)-cobalt (III) Complexes1-3 | |
Wooster | The Structure of Metal Ketyls. II. The Dissociation of Alkali Metal Pinacolates to Metal Ketyls in Liquid Ammonia Solution | |
DE1223396B (en) | Process for the preparation of trisodium salts of the zinc complexes of diaethylenetriamine-N, N. N ', N ", N" -pentaacetic acid and of triaethylenetetramine-N, N, N', N ", N" ', N "' - hexaacetic acid | |
Fargher et al. | The Chemotherapy of Antimony. Comparison of the Antimonyl Tartrates with the Organic Compounds of Antimony | |
US1906666A (en) | Process for making bismuth sodium gluconate and colloidal solution produced thereby | |
KR850000150B1 (en) | Method of preparing vindesine sulfate | |
US1856792A (en) | Anhydrotjs-alkali-metal salts of s | |
AT233020B (en) | Process for the preparation of new chelate compounds | |
Belcher et al. | The determination of fluorine by the lead chlorofluoride method in compounds containing halogens, sulphur, phosphorus and arsenic | |
Morgan et al. | CCLVIII.—Researches on residual affinity and coordination. Part XXII. Optically active salicylatocobalt diethylenediammines | |
Mackenzie | I.—Mandeliminohydrin | |
DE182217C (en) | ||
US2067747A (en) | Electrolytes for plating rhodium and methods of making the same | |
US1986749A (en) | Manufacturing of stable solutions of the sodium salt of diaminodioxy-arsenobenzene-methylensulphinic acid and the product | |
DE243469C (en) | ||
Cunningham et al. | CLXXVI.—Studies on the cobaltinitrites | |
DE2611602A1 (en) | Stable iodine complexes with amides ureas and lactams - useful in disinfectants as bactericides and fungicides | |
DE947333C (en) | Process for the production of crystallized islet hormone preparations |